Last week brought both significant victories and ongoing challenges for the pro-life movement. These developments directly impact our members and their work across the country.
In a major win at the U.S. Supreme Court, First Choice Women’s Resource Centers v. Davenport was decided unanimously, 9–0, in favor of First Choice. The Court ruled that First Choice, a New Jersey pregnancy resource center, could not be forced to turn over more than a decade’s worth of sensitive documents, including materials related to abortion pill reversal, as well as confidential donor and client information. Writing for the Court, Justice Neil Gorsuch affirmed that New Jersey Attorney General Matthew Platkin’s demands violated the First Amendment.
As ADF Counsel Erin Hawley, who argued the case in December, explained:
“In this resounding victory, the Supreme Court held to its long-standing precedent of recognizing that the Constitution protects First Choice and its donors from demands by a hostile state official to disclose donor identities and contact information.”
This decision is not only a victory for First Choice; it strengthens protections for pro-life organizations nationwide, including our members who serve in pregnancy centers and work tirelessly to support women and their preborn children.
At the same time, our partners at Alliance Defending Freedom (ADF) remain engaged in a critical legal battle over abortion drugs. In Louisiana v. FDA, the Fifth Circuit granted a motion to stay enforcement, immediately halting (temporarily while the full case works its way through the courts) the dispensing of abortion drugs without an in-person visit, ceasing the FDA’s reckless mail-order abortion scheme.
Abortion drug manufacturers GenBioPro and Danco, quickly appealed the decision to the U.S. Supreme Court. In response, the Supreme Court issued a seven-day administrative stay (pausing the Fifth Circuit’s decision), which is an interim step that allows time for the Court to consider the manufacturers’ emergency application. While this is not a final ruling, it underscores the high stakes of the case and the ongoing legal uncertainty surrounding the distribution of abortion drugs.
In light of these developments, AAPLOG issued the following statement:
“Just when women and preborn children were about to receive even the most basic safety protections, abortion manufacturers intervened to protect their bottom line.
Women deserve real medicine—not a mail-order workaround that serves the abortion industry. So-called ‘telehealth distribution’ of mifepristone does not provide genuine medical oversight. There is no exam, no ultrasound, no screening for coercion, and no accountable physician when complications arise.
This is a transaction, not a medical interaction. Women and their preborn children deserve better.
The Supreme Court should allow the Fifth Circuit’s ruling to stand.”
AAPLOG will be filing an amicus brief with the Supreme Court in support of Louisiana. We also exposed GenBioPro on social media, revealing in our undercover video that their abortion pills were distributed without ID or confirmation of pregnancy.
A national webcast was held on May 5 to celebrate and explain the victory, featuring Erin Hawley, AAPLOG’s Dr. Susan Bane, and pregnancy center leaders. You can watch the replay here.
During this historic time for the pro-life movement, make sure to stay up to date by following AAPLOG and ADF on Instagram, X, and Facebook. Also be sure to watch tomorrow’s (May 7) episode of OBservations, our weekly podcast, as we delve into this case with Erik Baptist, senior counsel at ADF and head of their Life Division.
